Related references
Note: Only part of the references are listed.Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients
Shawn F. J. Whelan et al.
BLOOD (2013)
Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy
Jenny Klintman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A
J. Klintman et al.
HAEMOPHILIA (2013)
Enhancing the pharmacokinetic properties of recombinant factorVIII: first-in-human trial of glycoPEGylated recombinant factorVIII in patients with hemophiliaA
A. Tiede et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein
R. T. Peters et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)
M. J. Manco-Johnson et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Factor VIII Products and Inhibitor Development in Severe Hemophilia A
Samantha C. Gouw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
Jennifer A. Dumont et al.
BLOOD (2012)
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
Jerry S. Powell et al.
BLOOD (2012)
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
Samantha C. Gouw et al.
BLOOD (2012)
F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity
C. H. Miller et al.
HAEMOPHILIA (2012)
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
L. A. Valentino et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2012)
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
Baisong Mei et al.
BLOOD (2010)
Improvements in factor concentrates
David Lillicrap
CURRENT OPINION IN HEMATOLOGY (2010)
Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance
V. Terraube et al.
HAEMOPHILIA (2010)
Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII
M. Recht et al.
HAEMOPHILIA (2009)
A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor
Lisa Gallinaro et al.
BLOOD (2008)
The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype
Maurizio Margaglione et al.
HAEMATOLOGICA (2008)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Barriers to compliance with prophylaxis therapy in haemophilia
MR Hacker et al.
HAEMOPHILIA (2001)
Share Paper
